Compare GH & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GH | SNN |
|---|---|---|
| Founded | 2011 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | 16988 |
| Industry | Medical Specialities | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 14.3B |
| IPO Year | 2018 | N/A |
| Metric | GH | SNN |
|---|---|---|
| Price | $91.48 | $34.15 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 2 |
| Target Price | ★ $119.79 | $36.25 |
| AVG Volume (30 Days) | ★ 2.1M | 736.5K |
| Earning Date | 05-07-2026 | 03-16-2026 |
| Dividend Yield | N/A | ★ 2.19% |
| EPS Growth | ★ 6.74 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $982,021,000.00 | N/A |
| Revenue This Year | $33.30 | $8.58 |
| Revenue Next Year | $28.27 | $5.60 |
| P/E Ratio | ★ N/A | $64.97 |
| Revenue Growth | ★ 32.88 | N/A |
| 52 Week Low | $36.36 | $26.02 |
| 52 Week High | $120.74 | $38.79 |
| Indicator | GH | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 57.17 |
| Support Level | $89.32 | $32.03 |
| Resistance Level | $101.77 | $37.23 |
| Average True Range (ATR) | 5.54 | 0.57 |
| MACD | 0.65 | 0.28 |
| Stochastic Oscillator | 69.78 | 83.48 |
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.